



Certificate of Mailing		
Date of Deposit: <u>February 3, 2005</u>		Label Number: <u>EV272783166US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
Elvis De La Cruz		
Printed name of person mailing correspondence		Signature of person mailing correspondence
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number: 50361/002001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		U.S. Application Number: <b>10/523542</b>
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/CA03/01185	August 7, 2003	August 7, 2002
TITLE OF INVENTION:	AMINO BENZOTHAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY	
APPLICANTS FOR DO/EO/US:	Jailall Ramnauth et al.	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)).	
4.	<input checked="" type="checkbox"/> The U.S. has been elected.	
5.	A copy of the International Application (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. Is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	An English language translation of the International Application into English (35 U.S.C. § 371(c)(2)). <input type="checkbox"/> a. is transmitted herewith. <input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input checked="" type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).	
10.	<input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371 (c)(5)).	
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input checked="" type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 is included.	
13.	<input checked="" type="checkbox"/> A preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A power of attorney and/or change of address letter.	
16.	<input type="checkbox"/> Request for Deferred Examination.	
17.	<input checked="" type="checkbox"/> Application Data Sheet.	
18.	<input checked="" type="checkbox"/> Other items or information: PCT Request, PCT General Power of Attorney from Neuraxon	

19. <input checked="" type="checkbox"/> The following fees are submitted:						
Basic National Stage Fee \$300				\$300.00		
National Stage Search Fee: \$500				\$500.00		
National Stage Examination Fee: \$200				\$200.00		
Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).				\$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Total claims	33 - 20 =	13	x \$50	\$ 650.00		
Independent claims	3 - 3 =	0	x \$200	\$ 0		
Multiple dependent claims (if applicable)			+ \$360	\$ 0		
Application Size Fee: Additional fee for specification and drawings in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
TOTAL SHEETS	EXTRA SHEETS	Number of each additional 50 sheets or fraction thereof (round up to a whole number)	RATE			
83-100=	0/50=		X\$250	\$ 0		
TOTAL OF ABOVE CALCULATIONS =				\$1650.00		
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status under 37 C.F.R. § 1.27				\$ 825.00		
SUBTOTAL =				\$ 825.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).				+	\$	
TOTAL NATIONAL FEE =				\$ 825.00		
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.				+	\$ 80.00	
TOTAL FEES ENCLOSED =				\$ 905.00		
				Amount to be refunded	\$	
				Charged	\$	
<input checked="" type="checkbox"/> a. Enclosed is a check for \$905.00 to cover the total fees. <input type="checkbox"/> b. Enclosed is a check for [**\$300/\$150**] to cover the basic national stage fee; no other fees are being paid at this time. <input type="checkbox"/> c. Please charge my Deposit Account No. 03-2095 in the amount of \$[**] to cover the above fees. <input checked="" type="checkbox"/> d. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.						
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO:						
Karen L. Elbing, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110-2214  Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559				 Signature Karen L. Elbing, Ph.D. Reg. No. 35,238		